Results 61 to 70 of about 22,314 (175)

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Azacitidine-induced bullous pemphigoid-like localized toxic reaction [PDF]

Einstein (São Paulo)
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation ...
Rodrigo Brêtas Emerich Nogueira, Nelson Hidekazu Tatsui, Laura Ramos de Almeida, Marcella Soares Pincelli, Celina Wakisaka Maruta, José Antonio Sanches, Elvira Deolinda Rodrigues Pereira Velloso, Youko Nukui   +7 more
doaj   +1 more source

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Haematologica, 2023
Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ...
Thomas Pabst, Norbert Vey, Lionel Adès, Ulrike Bacher, Mario Bargetzi, Samson Fung, Gianluca Gaidano, Domenica Gandini, Anna Hultberg, Amy Johnson, Xuewen Ma, Rouven Müller, Kerri Nottage, Cristina Papayannidis, Christian Recher, Carsten Riether, Priya Shah, Jeffrey Tryon, Liang Xiu, Adrian F. Ochsenbein   +19 more
doaj   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver

Journal of Investigative Medicine High Impact Case Reports
Azacitidine and venetoclax are important anti-neoplastic agents used in the treatment of acute myeloid leukemia. Azacitidine has been implicated to cause nonhepatic ischemic injury. Here we report a case of severe, short latency drug-induced liver injury
Dilara Hatipoglu MD, Arsia Jamali MD, MPH, Emily Sheng BA, K. Rajender Reddy MD   +3 more
doaj   +1 more source

Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis.

PLoS ONE, 2022
IntroductionElderly patients with acute myeloid leukemia not eligible for intensive antileukemic therapy are treated with less intensive therapies, uncertainty remains regarding their relative merits.ObjectivesTo compare the effectiveness and safety of ...
Luis Enrique Colunga-Lozano, Fernando Kenji Nampo, Arnav Agarwal, Pinkal Desai, Mark Litzow, Mikkael A Sekeres, Gordon H Guyatt, Romina Brignardello-Petersen   +7 more
doaj   +1 more source

Fatal Bone marrow necrosis following azacitidine and granulocyte colony-stimulating factor administration in a patient with high-risk myelodysplastic syndrome [PDF]

, 2015
　Azacitidine, which has the capacity to induce DNA hypomethylation in vitro, is currently available for treatment of myelodysplastic syndrome (MDS). As a result of some trials, azacitidine has been recently recommended as a frontline therapy for elderly ...
加藤 丈夫, 加藤 裕一, 塩野 洋介, 山田 茜, 鈴木 郁子   +4 more
core   +1 more source

HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]

, 2017
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa, Budillon, Alfredo, Krings, Gregor, Munster, Pamela N, Park, Jeenah, Pawlowska, Nela, Rosenblum, Michael D, Terranova-Barberio, Manuela, Thomas, Scott   +8 more
core   +1 more source

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

Experimental Hematology & Oncology, 2020
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen, Weiwen You, Sitian Yang, Xin Du   +3 more
doaj   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source